- Home
- SIEB vs AGEN Comparison
SIEB vs AGEN Comparison
Compare SIEB & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIEB
- AGEN
- Stock Information
- Founded
- SIEB 1886
- AGEN 1994
- Country
- SIEB United States
- AGEN United States
- Employees
- SIEB N/A
- AGEN N/A
- Industry
- SIEB Investment Bankers/Brokers/Service
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SIEB Finance
- AGEN Health Care
- Exchange
- SIEB Nasdaq
- AGEN Nasdaq
- Market Cap
- SIEB 94.9M
- AGEN 96.2M
- IPO Year
- SIEB N/A
- AGEN 2000
- Fundamental
- Price
- SIEB $2.82
- AGEN $3.50
- Analyst Decision
- SIEB
- AGEN Buy
- Analyst Count
- SIEB 0
- AGEN 3
- Target Price
- SIEB N/A
- AGEN $10.50
- AVG Volume (30 Days)
- SIEB 15.1K
- AGEN 416.5K
- Earning Date
- SIEB 11-12-2024
- AGEN 03-13-2025
- Dividend Yield
- SIEB N/A
- AGEN N/A
- EPS Growth
- SIEB 61.43
- AGEN N/A
- EPS
- SIEB 0.27
- AGEN N/A
- Revenue
- SIEB $83,357,000.00
- AGEN $160,427,000.00
- Revenue This Year
- SIEB N/A
- AGEN N/A
- Revenue Next Year
- SIEB N/A
- AGEN $36.13
- P/E Ratio
- SIEB $10.59
- AGEN N/A
- Revenue Growth
- SIEB 27.81
- AGEN 59.00
- 52 Week Low
- SIEB $1.41
- AGEN $2.50
- 52 Week High
- SIEB $3.34
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- SIEB 42.28
- AGEN 52.20
- Support Level
- SIEB $2.86
- AGEN $3.39
- Resistance Level
- SIEB $3.14
- AGEN $4.10
- Average True Range (ATR)
- SIEB 0.12
- AGEN 0.32
- MACD
- SIEB -0.02
- AGEN 0.00
- Stochastic Oscillator
- SIEB 23.68
- AGEN 39.25
About SIEB Siebert Financial Corp.
Siebert Financial Corp is a holding company. It conducts retail discount brokerage business through its wholly-owned subsidiary. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).